We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for ranibizumab (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
ranibizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection solution
Indication
For the treatment of preterm infants with retinopathy of prematurity (ROP)
Therapeutic area
Ophthalmology